Fig. 2: Neoantigen-specific immunological monitoring. | npj Precision Oncology

Fig. 2: Neoantigen-specific immunological monitoring.

From: Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer

Fig. 2: Neoantigen-specific immunological monitoring.The alternative text for this image may have been generated using AI.

a Scans of ELISPOT (left panel) and quantification (right panel) results showed day62 PBLs (after DC vaccination, before ICI treatment) and day245 PBLs (after the combination treatment) generated more IFN-γ spots than day-6 PBLs (before vaccination) when induced by ASP pools 1 or 2. ASP pool 1, 15mer assay mutant peptides pool of TMEM38B F251V, TIGD3 V118M, ZZEF1 R898H, and URB1 R421W; ASP pool 2, 15mer assay mutant peptide pool of DLEC1 R331C, TMTC1 C313Y, MTA2 R92W, and TDP1 K112Rfs.101. The positive control for ELISPOT was PMA/ionomycin at the concentration of 1 ng/mL PMA and 500 ng/mL ionomycin. The control is media only. b Mapping of CD8+ T cells response to each 15mer peptide. Each 27mer mutant peptide was cutting into four 15mer peptides (denoted by blue, red, black, and orange bars) whose start and end positions in the 27mer peptide are 1-to-15, 5-to-19, 9-to-23, and 13-to-27 (also shown in Supplementary Fig. 3). Dotted line, 2 folds of mock (media only); *, mutant epitope with SFC number > 2 folds than that of mock. c ELISPOT assays showed that 5 out of 6 tested mutant peptides, but not their corresponding WT peptides, specifically activated CD8+ T cells. Data shown here were the mean value of two replicates. d Total frequency of neoantigen-specific TCRB clones increased during vaccination. e Neoantigen-specific TCRB clones, whose frequencies were in top 10 in tumor tissue, changed in PBLs during vaccination.

Back to article page